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The role of Interleukin-10 and 13 in tuberculosis-
associated pulmonary dysfunction 
 
Abstract 
Background: Pulmonary dysfunctions are frequently encountered after tuberculosis 
treatment in clinical practice. In the present study, the role of interleukin-10 and 13 in a 
tuberculosis-associated pulmonary dysfunction was investigated. 
Methods: This is a semi-experimental study on 40 patients selected from referral 
tuberculosis care center in Birjand, Iran, during 2015-2017. The cases with major medical 
disorders including those with underlying lung disease were excluded from the study. 
Informed consent was prepared from each patient, and then blood sample was obtained, 
serum was extracted and refrigerated at -70 C° at the start (time 1), 2 months (time 2) and 
6 months (time 3) after onset of treatment for tuberculosis. Spirometry was also performed 
at time 2. Finally, 24 patients completed the study. 
Results: Of the 24 patients with the mean age of 60.87±21.50 years in the study, 9 (37%) 
were males and 15 (62.5%) were females. Abnormal spirometry was observed in 20 
(83.3%) subjects at time 2, of whom 12 (60%) were restrictive and 8 (40%) obstructive. 
The mean changes of interleukin 10 from the start to end of the treatment were 
89.00±89.47 (P=1.00), -29.36±40.21 (P=0.02) and 3.70±29.98 (P=0.1) in patients with 
normal, obstructive and restrictive spirometery, respectively (normal vs obstructive and 
restrictive; p<0.01). While in interleukin 10, changes for interleukin-13 were 
77.90±145.97, 6.35±133.10 and -13.35±46.66 (P=0.4), respectively. 
Conclusion: Upregulation of IL-10 during tuberculosis treatment might be considered as a 
protective factor against lung dysfunction. In patients with obstructive form, there was a 
marked decrease in interleukin-10. 
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Posttuberculosis pulmonary dysfunction presented as restrictive or obstructive 
spirometry patterns are frequently reported (1-4). Twenty percent of patients with chronic 
obstructive pulmonary disease (COPD) have never smoked (5). Inflammatory mechanisms 
at the origin of infection or autoimmunity play an essential role in COPD pathogenesis (5, 
6). In this sense, pulmonary tuberculosis was considered as a risk factor for COPD. The 
relationship of tuberculosis with COPD was well-described in PLATINO and BOLD 
studies (7, 8). Cytokines are humoral factors with important role in the regulation of 
immune response. Interleukin 10 and 13 are classified as Th-2 related cytokines, 
participating in asthma and COPD pathogenesis. While interleukin 13 is considered as 
inflammatory promoting, Interleukin 10 has an anti-inflammatory effect and has a low 
level in patient with asthma and COPD (9-11). Inverse relationship between severity of 
COPD and serum levels of Interleukin 10 has also been approved (12). 
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Interleukin 10 level in the bronchoalveolar lavage (BAL) 
of patients with idiopathic pulmonary fibrosis (fibrotic with 
little inflammation) is higher than the patients with other 
ILD diseases with abundant inflammation (13). Conversely, 
interleukin 13 is known as a profibrotic factor and its 
biologic targeting could prevent fibrosis (14). Some studies 
have revealed the changes of interleukin 10 and 13 in 
relation to pathology of pulmonary tuberculosis. IL-10 gene-
disrupted (IL-10 KO) mice get into increased inflammation 
and injury of lung during pulmonary mycobacterium 
tuberculosis infection (15). In a reverse order, IL-10 
transgenic mice encountered with decreased inflammation, 
spread of the disease and early death (16). IL-13-over-
expressing mice are associated with more necrosis in 
granuloma and getting more similarity with post primary 
tuberculosis (17). Interleukin 13 also increases during active 
tuberculosis (18). Considering the role of interleukin 10 and 
13 in pathogenesis of asthma and COPD and also 
considering occurrence of post tuberculosis pulmonary 
dysfunction, the role of Interleukin-10 and 13 with 
respiratory dysfunction during treatment of pulmonary 
tuberculosis are investigated in the present study 
 
 
Methods 
This is an experimental study on 40 new adult cases 
(over 12 years old) of pulmonary tuberculosis selected from 
referral tuberculosis care center in Birjand, Iran, during 
2015-2017, regardless of whether TB is primary or secondary. 
Informed consent to attendance in the study was obtained 
from all patients. Patients with any underlying disease other 
than pulmonary tuberculosis and also smokers were excluded 
from the study. The diagnostic criteria were initially based 
on clinical and radiologic evidence compatible with 
pulmonary tuberculosis in the presence of one of the 
following conditions. Definitive diagnosis was confirmed by 
culture of sputum or BAL for mycobacterium tuberculosis 
(MTB) in all cases.  
1. Two samples of sputum smear positive for MTB 
2. One sample of  sputum smear and one sputum culture 
positive for MTB 
3. One sample of BAL smear and one BAL culture positive 
for MTB 
4. One sample of BAL or sputum smear/culture positive for 
MTB in patients with radiological and clinical findings 
strongly suggestive of pulmonary tuberculosis  
Blood sample (5ml) was obtained, serum extracted and 
refrigerated at -70 C° from eligible patients at times of start 
(time 1), 2 months (time 2) and 6 months(time 3) after onset 
of treatment for pulmonary tuberculosis. All patients were 
treated free of charge based on WHO (World Health 
Organization) protocols for tuberculosis treatment by the 
referral tuberculosis care center in Birjand, Iran. Every two 
months, examinations for all patients were done by the 
pulmonologist during the course of tuberculosis treatment. 
Treatment response was confirmed at the end of treatment by 
clinical findings and study of chest radiography, smear and 
culture of sputum or BAL samples. IL-10 and IL-13 
measurements were performed by ELISA method using the 
INTEGRA 400 device and the Roche Diagnostics Kit, 
Germany and reported quantitatively. Inter and intra assay 
coefficient of variation respectively for both interleukin 10 
and 13 was <12% and <10%. Spirometry was performed at 
time 2. Data are recorded and analyzed using SPSS software 
(Version 23). Shapiro-Wilk test was used to evaluate the 
normality of the data. Mann-Whitney and Kruskal-Wallis 
tests were used to compare means in 2 and 3 independent 
groups with non-normal distribution. We used Friedman test 
to compare the mean of repeated measures with non-normal 
distribution. The approval number of the study was 
IR.BUMS.REC.1395.70 recorded in the Ethics Committee of 
Birjand University of Medical Sciences, Birjand, Iran.  
 
 
Results 
From 40 recruited patients, 24 cases with the mean age of 
60.87±21.50 years completed the study. Out of 24 cases, 9 
(37.5%) were men and 15(62.5%) were women. Patterns of 
spirometry were normal, restrictive and obstructive in 
4(16.7%), 12(50%) and 8(33.3%) cases, respectively. The 
mean reduction of IL-10 during treatment in TB patients 
with obstructive spirometry was -29.36±40.21 (P=0.02).  On 
the contrary, IL-10 was set up in patients with normal 
spirometry (89.07±89.47, P=0.1) (table 1). Mean changes in 
IL-10 and 13 levels from start to end of study (time1 to 
time3) showed a strong negative (r=-0.72, P=0.04), a weak 
negative (-0.08 (0.79), and a strong positive (0.87 (0.12) 
relationships in patients with obstructive, restrictive and 
normal spirometry respectively (table 2).  There were also 
significant relationships between IL-10 and IL-13 in patients 
with obstructive spirometry at times 2 (r= 0.81, P=0.01) and 
3 (r= 0.76, P=0.02) (table 2).  
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Table1: Mean comparison of interleukin 10 and 13 between and within spirometry pattern groups alongside of TB treatment 
Interleukin 
Restrictive(N=12) 
(Mean±SD) 
Obstructive( N=8) 
(Mean±SD) 
Normal (N=4) 
(Mean±SD) 
 
P value 
Interleukin -10 (time1) 85.13±43.71 124.70±91.41 79.52±49.35 0.15 
Interleukin -10 (time2) 91.11±65.25 111.06±103.90 100.05±55.37 0.85 
Interleukin -10 (time3) 
P value(within group) 
Mean changes 
88.83±66.34 
1.00 
3.70±29.98 
95.33±61.51 
0.02 
-29.36±40.21 
168.60±137.15 
0.10 
89.07±89.47 
0.18 
 
0.00* 
Interleukin -13 (time1) 
Interleukin -13 (time2) 
Interleukin -13(time3) 
P value(within group) 
Mean changes 
115.98±49.92 
105.50±29.62 
102.62±34.97 
0.26 
-13.35±46.66 
138.72±53.42 
138.26±108.73 
145.07±107.74 
0.22 
6.35±133.10 
126.52±62.07 
128.32±32.90 
204.42±185.68 
1.00 
77.90±145.97 
0.67 
0.37 
0.31 
 
0.4 
*: Normal versus restrictive and obstructive with statistically significant different 
time1: initiation of TB treatment, time 2: at two months after starting TB treatment, time 3: at end of 6 months TB therapy 
 
Table 2: Relationship between changes of IL-10 and 13 in all patients, and patients with normal, restrictive and obstructive spirometry 
Time of interleukin test Interleukin-10 Interleukin-13 Correlation  (P-value) 
All patients    
Time 1 97.38±64.56 125.32±51.68 0.3 (0.14)* 
Time 2 99.25±76.19 120.22±66.31 0.63 (0.00)* 
Time3  104.29±81.13 133.74±100.17 0.75 (0.00)* 
Mean changes(from time1 to 3) 6.90±60.03 8.42±101.49 0.19 (0.35)* 
Normal spirometry group(N=4)    
Time 1  79.52±49.35 126.52±62.07 0.88 (0.11)# 
Time 2 100.05±55.37 128.32±32.90 0.32 (0.67)≠ 
Time 3 168.60±137.15 204.42±185.68 0.92 (0.07)≠ 
Mean changes(from time1 to 3) 89.07±89.47 77.90±145.97 0.87 (0.12)≠ 
Restrictive spirometry group( N=12)    
Time 1 85.13±43.71 115.98±49.92 0.15 (0.63)* 
Time 2 91.11±65.25 105.50±29.62 0.68 (0.04)* 
Time 3 88.83±66.34 102.62±34.97 0.72  (0.00)* 
Mean changes(from time1 to 3) 3.70±29.98 -13.35±46.66 -0.08 (0.79)* 
Obstructive spirometry group(N=8)    
Time 1 124.70±91.41 138.72±53.42 -0.15 (0.72)≠ 
Time 2 111.06±103.90 138.26±108.73 0.81 (0.01)* 
Time 3 95.33±61.51 145.07±107.74 0.76 (0.02)* 
Mean changes(from time1 to 3) -29.26±40.21 6.35±133.10 -0.72 (0.04)≠ 
*Spearman's rho test, ≠Pearson, time1: initiation of TB treatment, time 2: at the end of 2 months TB treatment, time 3: at the end of 6 months TB therapy 
 
Discussion 
The prevalence of abnormal spirometry was 83.3% in our 
study 2 months after starting pulmonary tuberculosis  
treatment. Meanwhile, the prevalence of post tuberculosis 
abnormal spirometry reported 74% in Tanzania and 59% in  
 
America (19, 20). Taken together these studies mean that 
lung dysfunction appears and progress alongside with 
pulmonary tuberculosis regardless of antibacterial treatment. 
The frequency of restrictive, obstructive and normal 
spirometry was 50%, 33.3% and 16.7% respectively in our 
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study. However, reported frequency of restrictive, 
obstructive and mixed type of spirometry were respectively 
31%, 15% and 13% in America (20), 13%, 42% and 19% in 
Tanzania (19) 29.7%, 55.3%, and 14.8% in Pakistan (21). 
More prevalence of restrictive spirometry in our study may 
be due to performing spirometry throughout the course 
during instead of post tuberculosis treatment.  Scientific 
scholars have much emphasis on the development of post 
tuberculosis chronic obstructive pulmonary disease and 
pulmonary tuberculosis has been considered as a major risk 
factor for COPD by GOLD (2016) (22). 
Serum levels of IL-10 showed significant upregulation in 
patients with normal and downregulation with obstructive 
spirometry alongside tuberculosis treatment in our study. IL-
10 is known as an anti-inflamatory cytokine and its 
production in patients with pulmonary infection leads to less 
inflammation-related lung damages (23). Since tuberculosis 
is considered as a risk factor for COPD (24), change in IL-10 
can be raised to the development of post tuberculosis lung 
dysfunction (9-11, 25). Patients with restrictive spirometry 
did not show significant change in IL-10 during tuberculosis 
treatment in our study. The finding can be in consistent with 
the assumption that high levels of IL-10 can help in 
preventing post infectious diseases tissue damage (26). 
Interleukin 10 can also be considered as an anti-
inflammatory drug in preventing pulmonary fibrosis in 
patients with idiopathic pulmonary fibrosis (IPF) (27). 
Changes in IL-13 were not significant during tuberculosis 
treatment in patients with normal, restrictive or obstructive 
spirometry in our study. There is not much information about 
the role of interleukin 13 in patients with tuberculosis and 
also post tuberculosis complications. It was claimed in a 
study that expression of IL-13 was upregulated in Indian 
children with latent TB compared with that in controls (28). 
Despite claimed role of IL-13 in pathogenesis of 
tuberculosis, its relationship with respiratory dysfunction is 
not clear. The role of IL-13 in respiratory dysfunction is 
even more questioned in patients with COPD and asthma in 
a study conducted by Grubek-Jaworska H et al. (29). Patients 
with obstructive spirometry showed inverse relationship 
between changes of IL-10 and IL-13 from start to end of 
therapy. The positive relationship, however, is observed in 
patients with normal spirometry. Other studies have also 
shown that interleukin 10 and 13 have an inverse 
relationship in patients with COPD and asthma (9-11). Based 
on significant reduction of IL-10 in tuberculosis patients 
with obstructive spirometry in our study, it can be concluded 
that IL-10 plays a central role in preventing respiratory 
dysfunction. This assumption was also confirmed by a study 
that explained more severe COPD in condition with low 
levels of IL-10 (12). Limitations of the study: The most 
important limitation in our study was that of not-having 
spirometry before starting TB treatment. To minimize these 
effects, the patients with other risk factors for COPD were 
excluded from the study. Low number of participants was 
another limitation of this study.  
Conclusion: Respiratory dysfunction as a post pulmonary 
tuberculosis complication is common. IL-10 and IL-13 are 
two cytokines that undergo changes in the course of 
tuberculosis and can be raised in pathogenesis of lung 
dysfunction.  It seems that the low levels of interleukin 10 
play an essential role in the emergence of tuberculosis 
related obstructive and also restrictive pulmonary 
dysfunction.   
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